logo
Share SHARE
FONT-SIZE Plus   Neg

MMRC And Synta Pharma Begin Ganetespib Clinical Trial In Multiple Myeloma

Synta Pharmaceuticals Corp. (SNTA) and the Multiple Myeloma Research Consortium or MMRC announced the start of a clinical trial evaluating ganetespib, a second generation Hsp90 inhibitor being developed by Synta Pharmaceuticals, as a single agent and in combination with the proteasome inhibitor bortezomib (VELCADE) for the treatment of relapsed multiple myeloma.

The trial, made possible by the funding up to $1 million by the Multiple Myeloma Research Foundation (MMRF), will be conducted through the MMRC. The MMRC is a consortium of sixteen world-renowned academic institutions and community centers whose mission is to accelerate the development of novel and combination treatments for patients with multiple myeloma by promoting and facilitating collaborative research between industry and academia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
New York's landmark Waldorf Astoria hotel will be shut for up to three years starting spring 2017 as its Chinese owner Anbang Insurance Group Co. plans to convert most of its 1,413 hotel rooms into luxury condominiums, according to media reports. Starbucks Corp., for the first time, will offer a single-origin coffee from India to customers in the U.S. under an expansion of the specialty coffee retailer's joint venture partnership with Indian conglomerate Tata Group. Starbucks customers in the U.S. will be able to experience a rare, small-lot coffee from the Tata Nullore Estates located in the Coorg region of India. For the Independence Day week-end, starting June 30, travel volume will be a record this year, predicts the American Automobile Association or AAA. Friday and Monday afternoons are expected to be the peak hours. Cruising seems to be a favorite travel mode this year with 35 percent increase from last...
comments powered by Disqus
Follow RTT